The Rationale of Diarylheptanoid in Ameliorating Dimethylaminoazobenzene-Induced Hepatocellular Carcinoma: Methodical Implication

Document Type : Original Article

Authors

1 Division of biochemistry, Department of Chemistry, Faculty of Science, Tanta University, Egypt.

2 Department of Clinical Trial Research Unit and Drug Discovery, Egyptian Liver Research Institute and Hospital (ELRIAH), Mansoura, Egypt

3 Physiology Department, Faculty of Science, Tanta University, Tanta, Egypt.

Abstract

Hepatocellular carcinoma (HCC) is the world's fifth leading cause of cancer and a major health problem in Egypt. At best, liver transplantation and surgical excision are the only therapy choices. As a result, there is a pressing need to research and assess different chemopreventive and therapeutic techniques that could be useful in the treatment of liver cancer. The most common environment in which HCC originates and advances is one of oxidative stress and inflammation. Phytochemicals, such as diarylheptanoids, which have powerful antioxidant and anti-inflammatory activities, are a viable alternative in the treatment of HCC. Anti-inflammatory, antioxidant, and anti-cancer effects are all present in it. Its effects can be inconsistent in some cases, with unknown consequences for human treatment. While additional research is needed to fully explain these inconsistencies, diarylheptanoid has the potential to be a disease-modifying and chemopreventive drug. As our study design rationale, we evaluate the data for diarylheptanoid's therapeutic potential in animal models. This methodological conclusion that verifies our hypothesis could lead to the identification of novel anticancer drug development methodologies.

Keywords

Files

Share

How to cite

Statistics